Ann: Investor webinar presentation, page-2

Nice prezzo. Fair bit of upside if get FDA approval for Protozoa 3-base. Had a good write up as well by Taylor-collison
”We initiate coverage with an Outperform recommendation and believe that the stock represents an attractive investment opportunity given the prospect of US commercialisation next year. Our base case valuation of $2.21/share ($2.16 fully diluted) assumes the enteric protozoan test achieves a 20% penetration of the US market, and that revenue from other EasyScreen tests in the US is 50% of enteric revenue, with a lag of 2 years. Our bull case valuation of $6.18/share assumes the enteric protozoa test achieves 50% market penetration. Our bear case valuation of $1.36/share assumes US launch is delayed by 2 years and achieves 20% market penetration, and no other tests are launched in the US.”

also have another test in for approval with FDA.